Targeted drug may prolong survival of patients with cervical cancer
A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer ...
Mar 10, 2014